Emeritus Research in Camberwell, is a pre-clinical consultancy services, IND site out of 10 sites proposed to be established in Australia.
IHL has completed a pre-IND meeting with the FDA to discuss the regulatory pathway for the development of IHL-675A in the United States and plan to open INDs for each of the three indications, the efficacy, safety and tolerability of IHL-675A.
IHL has been received Australia government's incentive rebates of up to 43.5% since Phase 1 onwards. The government support is a proof of revenue streams to help the company to be listed on Nasdaq in 3 months time.
Do you want to see your lover to get married overseas?
Gbab it. Hold it tight.
